Comparing Pulse Biosciences (NASDAQ:PLSE) and Bausch + Lomb (NYSE:BLCO)

Pulse Biosciences (NASDAQ:PLSE) and Bausch + Lomb (NYSE:BLCO) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by insiders. Comparatively, 1.4% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Pulse Biosciences and Bausch + Lomb”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350,000.00	11,973.94	-$72.78 million	($1.21)	-47.09
Bausch + Lomb	$5.10 billion	1.50	-$360.00 million	($0.31)	-68.87

Pulse Biosciences has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Pulse Biosciences has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.

Profitability

This table compares Pulse Biosciences and Bausch + Lomb’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-5,603.88%	-77.88%	-67.89%
Bausch + Lomb	-2.05%	5.01%	2.34%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Pulse Biosciences and Bausch + Lomb, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1	0	5	1	2.86
Bausch + Lomb	1	8	4	2	2.47

Pulse Biosciences currently has a consensus price target of $66.60, suggesting a potential upside of 16.88%. Bausch + Lomb has a consensus price target of $20.83, suggesting a potential downside of 2.42%. Given Pulse Biosciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Pulse Biosciences is more favorable than Bausch + Lomb.

Summary

Pulse Biosciences beats Bausch + Lomb on 8 of the 14 factors compared between the two stocks.

About Pulse Biosciences

Pulse Biosciences, Inc. develops medical devices using its proprietary nanosecond pulsed field ablation (nsPFA) technology. The technology delivers very short electrical pulses intended to disrupt targeted cells without relying on heat, with the goal of limiting effects on surrounding tissue. The company is developing nsPFA applications for cardiac electrophysiology and surgical oncology, including devices for tissue ablation. Its earlier CellFX System brought the technology to dermatology for treating certain benign skin lesions, marking an initial commercial application of the platform.

About Bausch + Lomb

Bausch + Lomb Corporation is an eye-health company that develops, manufactures and markets products for consumers, eye-care professionals and surgical teams. Its business spans vision care, pharmaceuticals and surgical devices. Its products include contact lenses and lens-care solutions, as well as eye-health medicines and nutritional supplements. The company also supplies equipment, technologies and related products used in eye surgery and other ophthalmic procedures. Founded in Rochester, New York, in 1853 by John Jacob Bausch and Henry Lomb, the company serves customers in more than 100 countries.